Portal de Periódicos da CAPES

ANDROPAUSE: A MISNOMER FOR A TRUE CLINICAL ENTITY

2000; Lippincott Williams & Wilkins; Volume: 163; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)67788-9

1527-3792

Álvaro Morales, Jeremy P.W. Heaton, Culley C. Carson,

Sexual Differentiation and Disorders

No AccessJournal of UrologyCLINICAL UROLOGY: Review Articles1 Mar 2000ANDROPAUSE: A MISNOMER FOR A TRUE CLINICAL ENTITY ALVARO MORALES, JEREMY P.W. HEATON, and CULLEY C. CARSON ALVARO MORALESALVARO MORALES , JEREMY P.W. HEATONJEREMY P.W. HEATON , and CULLEY C. CARSONCULLEY C. CARSON View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67788-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A progressive decrease in androgen production is common in males after middle age. The resulting clinical picture has been erroneously named male menopause or andropause. A more appropriate designation is androgen decline in the aging male (ADAM). The syndrome is characterized by alterations in the physical and intellectual domains that correlate with and can be corrected by manipulation of the androgen milieu. We review the epidemiological aspects of aging and endocrinological manifestations of ADAM, and provide recommendations for treatment and monitoring of these patients. Materials and Methods: We performed MEDLINE, Pubmed, Current Contents and Pharmaceutical Abstracts searches of relevant peer reviewed publications on andropause, male climacteric, adult hypogonadism and aging. In addition, conference proceedings were researched to provide a more complete review of the literature. Information was scrutinized and collated, and contributory data were reviewed and summarized. Results: ADAM is a clinical entity characterized biochemically by a decrease not only in serum androgen, but also in other hormones, such as growth hormone, melatonin and dehydroepiandrosterone. Clinical manifestations include fatigue, depression, decreased libido, erectile dysfunction, and alterations in mood and cognition. Conclusions: The onset of ADAM is unpredictable and its manifestations are subtle and variable, which has led to a paucity of interest in its diagnosis and treatment. Urological practice commonly includes a large proportion of men older than 50 years. Therefore, it is important for urologists to recognize the manifestations of and be familiar with evaluations necessary to document ADAM as well as its treatment and monitoring. References 1 Shakespeare, W.: Henry IV. Part 2 Google Scholar 2 United Nations Department for Economical and Social Information and Policy Analysis. Population Division. In: . New York: United Nations1995. Document 145. Google Scholar 3 : An aging humankind: is our future behind us?. Aging Male1998; 1: 8. Google Scholar 4 WHO: Epidemiology and Prevention of Cardiovascular Disease in Elderly People. In: . Geneva: WHO1995. Google Scholar 5 : Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol1998; 147: 750. Google Scholar 6 : Osteoporosis in patients receiving total androgen blockade therapy for prostate cancer. J Urol1998; 159: 336. abstract 1291. Google Scholar 7 : Effects of early hormonal therapy on bone in asymptomatic men with prostate cancer. J Urol1998; 159: 338. abstract 1298. Google Scholar 8 : Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin and prolactin secretion in men. J Clin Endocrinol Metab1997; 82: 3203. Google Scholar 9 : Clinical aspects of growth hormone deficiency in adults. Endocrinol Rev1995; 16: 63. Google Scholar 10 : Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine1997; 7: 41. Google Scholar 11 : Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab1994; 78: 669. Google Scholar 12 : Growth hormone substitution in adult growth-hormone deficient men augments androgen effect on the skin. Clin Endocrinol1997; 47: 29. Google Scholar 13 : Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized placebo-controlled trial. Ann Int Med1996; 125: 883. Google Scholar 14 : Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf)1998; 48: 59. Google Scholar 15 : Effect of growth hormone treatment on adult height of children with idiopathic short stature. N Engl J Med1999; 340: 502. Google Scholar 16 : Decreases in cerebral microvasculature with age associated with decline in growth hormone and insulin-like growth factor-I. Endocrinology1997; 138: 3515. Google Scholar 17 : Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab1998; 83: 3184. Google Scholar 18 : The adult growth hormone deficiency syndrome: signs, symptoms and diagnosis. Endocrinologist1998; 8: 8S. Google Scholar 19 : Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab1999; 84: 323. Google Scholar 20 : New dosage form for pulsatile delivery of melatonin: development and testing in animal and human subjects. Aging Male1998; 1: 141. Google Scholar 21 : Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol1995; 293: 327. Google Scholar 22 : The immunoneuroendocrine role of melatonin. J Pineal Res1993; 14: 1. Google Scholar 23 : Melatonin and the aging male. Aging Male1998; 1: 9. Google Scholar 24 : Cellular and molecular mechanisms mediating melatonin action. Aging Male1998; 1: 113. Google Scholar 25 : Clinical review 90: leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab1997; 82: 2771. Google Scholar 26 : Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab1998; 83: 3243. Google Scholar 27 : Strong association between serum levels of leptin and testosterone. Clin Endocrinol (Oxf)1997; 47: 237. Google Scholar 28 : Effects of androgens in men with the metabolic syndrome. Aging Male1998; 1: 129. Google Scholar 29 : The age-related decline of androgen levels in men: clinically significant?. Br J Urol1996; 78: 763. Google Scholar 30 : A long-term prospective study of the physiological and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl1992; 13: 297. Google Scholar 31 : Androgen behavior correlations in hypogonadal and eugonadal men: cognitive abilities. Horm Behav1998; 33: 85. Google Scholar 32 : Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol1995; 269: E820. Google Scholar 33 : Androgen administration to aging men. Endocrinol Metab Clin North Am1994; 23: 877. Google Scholar 34 : Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol1998; 156: 59. Google Scholar 35 : The localization of androgen receptors in human bone. J Clin Endocrinol Metab1997; 82: 3493. Google Scholar 36 : Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res1995; 43: 25. Google Scholar 37 : Circadian variation in testosterone, sex hormone-binding globulin and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl1989; 10: 366. Google Scholar 38 : Reproductive function in young fathers and grandfathers. J Clin Endocrinol Metab1982; 55: 676. Google Scholar 39 : Placebo therapy in benign prostatic hyperplasia. J Urol1997; 157: 330. abstract 1289. Google Scholar 40 : Chronic administration of dehydroepiandrosterone (DHEA) does not increase serum testosterone or prostatic specific antigen (PSA) in normal men. J Urol1998; 159: 74. abstract 278. Google Scholar 41 : Neuronal activities of dehydroepiandrosterone. Possible roles in brain development, aging, memory and affect. Ann NY Acad Sci1996; 774: 111. Google Scholar 42 : Neurosteroids: biochemistry, modes of action and clinical relevance. J Clin Endocrinol Metab1994; 78: 1003. Google Scholar 43 : Behavioral correlates of dehydroepiandrosterone and dehydroepiandrosterone sulfate. Aging Male1998; 1: 103. Google Scholar 44 : Hormone replacement for men. BMJ1996; 312: 859. Google Scholar 45 : The age of dehydroepiandrosterone. Lancet1995; 345: 1193. Google Scholar 46 : Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. Clin Endocrinol Metab1994; 78: 1360. Google Scholar 47 : Routine endocrine screening in impotence: significance and cost-effectiveness. Int J Impot Res1991; 3: 87. Google Scholar 48 : Routine endocrine screening in impotence: significance and cost effectiveness. Int J Impot Res1991; 3: 85. Google Scholar 49 : Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol1997; 158: 1764. Link, Google Scholar 50 : Testosterone supplementation in hypogonadal impotence: assessment of biochemical measurements and therapeutic outcomes. J Urol1997; 157: 849. Link, Google Scholar 51 : Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab1989; 69: 776. Google Scholar 52 : Oral androgens in the treatment of hypogonadal impotent men. J Urol1994; 152: 1115. Link, Google Scholar 53 : Drug therapy: androgens in men—uses and abuses. N Engl J Med1996; 334: 707. Google Scholar 54 : Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis1995; 38: 255. Google Scholar 55 : A ten year safety study of the oral androgen testosterone undecenoate. J Androl1994; 15: 212. Google Scholar 56 : Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril1982; 37: 425. Google Scholar 57 : Androgen treatment of hypogonadal men. J Clin Endocrinol Metab1992; 74: 1221. Google Scholar 58 : Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril1987; 47: 1004. Google Scholar 59 : Clinical review 85: emerging issues in androgen replacement therapy. J Clin Endocrinol Metab1997; 82: 3. Google Scholar 60 : Effects of testosterone replacement on HDL subfractions and apolipoprotein A/I containing lipoproteins. Clin Endocrinol (Oxf)1998; 48: 187. Google Scholar 61 : Effects of androgens on haemostasis. Maturitas1996; 24: 147. Google Scholar 62 : Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res1997; 2: 293. Google Scholar 63 : Androgens: risks and benefits. J Clin Endocrinol Metab1991; 73: 4. Google Scholar 64 : The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol1997; 158: 1775. Link, Google Scholar 65 : Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism. Endocr J1997; 44: 719. Google Scholar 66 : Effect of exogenous testosterone replacement on prostate specific androgen and prostate-specific membrane androgen levels in hypogonadal men. J Surg Oncol1995; 59: 246. Google Scholar 67 : Transdermal testosterone. Drugs1998; 55: 253. Google Scholar 68 : Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that aging enhances testosterone negative feedback. The Testoderm Study Group. Clin Endocrinol (Oxf)1997; 47: 317. Google Scholar 69 : Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J Endocrinol1996; 148: 254. Google Scholar 70 : Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA1989; 261: 2525. Google Scholar 71 : Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab1989; 68: 369. Google Scholar 72 : Effects of a permeation enhanced transtestosterone transdermal system on prostate parameters in previously treated or untreated hypogonadal males. Br J Uro1996; l77: 38. abstract. Google Scholar 73 : Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther1998; 20: 80. Google Scholar 74 : Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. Am J Contact Dermatol1997; 8: 102. Google Scholar 75 : An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf)1997; 47: 311. Google Scholar 76 : A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab1992; 74: 75. Google Scholar 77 : Pharmacology, pharmacokinetics and effects/side-effects of different androgen preparations. Aging Male1998; 1: 28. Google Scholar 78 : Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab1997; 82: 2386. Google Scholar 79 : Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol1997; 146: 609. Google Scholar 80 : The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis1996; 125: 1. Google Scholar 81 : The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb1994; 14: 701. Google Scholar 82 : Beneficial effects of testosterone undecenoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Jpn Heart J1997; 38: 73. Google Scholar 83 : Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc1993; 41: 149. Google Scholar 84 : Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metab1997; 82: 571. Google Scholar 85 : Effects of estrogens on the prostate. J Androl1994; 15: 97. Google Scholar 86 : Prostate volume in treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf)1994; 40: 341. Google Scholar 87 : Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab1992; 75: 1092. Google Scholar 88 : Androgen deficiency in aging men. Aging Male1998; 1: 16. Google Scholar 89 : Androgen supplementation in hypogonadal elderly menOctober 17–21, 1998; . Google Scholar 90 : Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res1998; 48: 3515. Google Scholar 91 : Effects of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol1998; 159: 441. Link, Google Scholar 92 : Androgen deficiency in ageing maleMay 1997; . Google Scholar 93 : Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology1999; 53: 423. Google Scholar 94 : Testosterone and the aging male. J Androl1997; 18: 103. Google Scholar 95 : Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry1998; 155: 1310. Google Scholar 96 : Testosterone treatment of an XXYY male presenting with aggression: a case report. Can J Psych1988; 33: 846. Google Scholar 97 : Androgens, cognitive function and mood in men. In: . New York: Parthenon Publican Group1996: 147. Google Scholar 98 : Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab1996; 81: 3578. Google Scholar 99 : Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impot Res1996; 8: 95. Google Scholar 100 : Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male1998; 1: 213. Google Scholar From the Department of Urology, Queen's University, Kingston, Ontario, Canada, and Department of Urology, University of North Carolina, Chapel Hill, North Carolina© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byEl-Sakka A and Hassoba H (2018) Age Related Testosterone Depletion in Patients With Erectile DysfunctionJournal of Urology, VOL. 176, NO. 6, (2589-2593), Online publication date: 1-Dec-2006.TSUJIMURA A, MATSUMIYA K, MATSUOKA Y, TAKAHASHI T, KOGA M, IWASA A, TAKEYAMA M and OKUYAMA A (2018) Bioavailable Testosterone With Age and Erectile DysfunctionJournal of Urology, VOL. 170, NO. 6, (2345-2347), Online publication date: 1-Dec-2003.Rhoden E, Teloken C, Sogari P and Souto C (2018) The Relationship Of Serum Testosterone To Erectile Function In Normal Aging MenJournal of Urology, VOL. 167, NO. 4, (1745-1748), Online publication date: 1-Apr-2002. Volume 163Issue 3March 2000Page: 705-712 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.KeywordsandrogenshypogonadismagingmenMetricsAuthor Information ALVARO MORALES More articles by this author JEREMY P.W. HEATON More articles by this author CULLEY C. CARSON More articles by this author Expand All Advertisement PDF downloadLoading ...